Conference news @infohep
Eight weeks of treatment with Epclusa cured almost all people receiving opioid substitution therapy
Keith Alcorn
Published: 12 April 2018
An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, Alison Boyle of Gartnavel Hospital, Glasgow, reported at the 2018 International Liver Congress in Paris on Thursday. Genotype 3 is especially common in people who inject drugs and former drug users. It has been considered 'harder to cure' although recent studies of newer agents in people with genotype 3 have shown high cure rates.
Continue reading......
Slides @ NATAP
8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort - (04/13/18)
New @infohep
New Hepatocellular carcinoma (HCC)
EASL updates liver cancer guidelines at International Liver Congress
Liz Highleyman / 7 hours ago
The European Association for the Study of the Liver (EASL) presented updated clinical practice guidelines for the management of hepatocellular carcinoma (HCC) during a special session at the 2018 International Liver Congress yesterday
New NAFLD
Cenicriviroc treatment improves liver fibrosis in people with NASH
Liz Highleyman / 7 hours ago
Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, continued to show an anti-fibrotic effect in people with non-alcoholic steatosis (NASH) after two years of follow-up, according to a
New Treatment for people who use drugs
Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy
Keith Alcorn / 18 hours ago
An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area...
Eight weeks of treatment with Epclusa cured almost all people receiving opioid substitution therapy
Keith Alcorn
Published: 12 April 2018
An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area, Alison Boyle of Gartnavel Hospital, Glasgow, reported at the 2018 International Liver Congress in Paris on Thursday. Genotype 3 is especially common in people who inject drugs and former drug users. It has been considered 'harder to cure' although recent studies of newer agents in people with genotype 3 have shown high cure rates.
Continue reading......
Slides @ NATAP
8 weeks sofosbuvir/velpatasvir in genotype 3 patients with significant fibrosis: Highly effective amongst an OST cohort - (04/13/18)
New @infohep
New Hepatocellular carcinoma (HCC)
EASL updates liver cancer guidelines at International Liver Congress
Liz Highleyman / 7 hours ago
The European Association for the Study of the Liver (EASL) presented updated clinical practice guidelines for the management of hepatocellular carcinoma (HCC) during a special session at the 2018 International Liver Congress yesterday
New NAFLD
Cenicriviroc treatment improves liver fibrosis in people with NASH
Liz Highleyman / 7 hours ago
Cenicriviroc, a drug that blocks both CCR5 and CCR2 receptors on immune cells, continued to show an anti-fibrotic effect in people with non-alcoholic steatosis (NASH) after two years of follow-up, according to a
New Treatment for people who use drugs
Eight weeks of treatment with Epclusa cured almost all people with HCV receiving opioid substitution therapy
Keith Alcorn / 18 hours ago
An eight-week course of sofosbuvir/velpatasvir (Epclusa) cured almost all people with hepatitis C genotype 3 without cirrhosis receiving treatment alongside opioid substitution therapy through community pharmacies or prisons in the Greater Glasgow area...
Pan-genotypic regimens
New affordable hepatitis C combination shows 97% cure rate
Keith Alcorn / 12 April 2018
The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and
New affordable hepatitis C combination shows 97% cure rate
Keith Alcorn / 12 April 2018
The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and
No comments:
Post a Comment